Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
RBC-transfusion guidelines update.
Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S. Gale RP, et al. Among authors: kiladjian jj. Leuk Res. 2012 May;36(5):659-60. doi: 10.1016/j.leukres.2012.01.023. Epub 2012 Feb 14. Leuk Res. 2012. PMID: 22336392 Free PMC article. No abstract available.
Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.
Passamonti F, Mora B, Giorgino T, Guglielmelli P, Cazzola M, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver R, Benevolo G, Albano F, Caramazza D, Rumi E, Merli M, Pietra D, Casalone R, Barbui T, Pieri L, Vannucchi AM. Passamonti F, et al. Among authors: kiladjian jj. Leukemia. 2017 Apr;31(4):970-973. doi: 10.1038/leu.2016.351. Epub 2016 Nov 25. Leukemia. 2017. PMID: 27885272 No abstract available.
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM. Passamonti F, et al. Among authors: kiladjian jj. Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31. Leukemia. 2017. PMID: 28561069
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.
Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A, Percy MJ, Schwemmers S, Gruender A, Kelley TW, Reading S, Pancrazzi A, McMullin MF, Pahl HL, Cross NC, Harrison CN, Prchal JT, Chomienne C, Kiladjian JJ, Barbui T, Grimwade D. Jovanovic JV, et al. Among authors: kiladjian jj. Leukemia. 2013 Oct;27(10):2032-9. doi: 10.1038/leu.2013.219. Epub 2013 Jul 17. Leukemia. 2013. PMID: 23860450 Free PMC article.
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.
Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Rossi G, Elli E, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Ruggeri M, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, De Stefano V, Harrison C, Rambaldi A. Barbui T, et al. Among authors: kiladjian jj. Leukemia. 2021 Feb;35(2):485-493. doi: 10.1038/s41375-020-01107-y. Epub 2021 Jan 7. Leukemia. 2021. PMID: 33414483 Free PMC article.
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.
Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T, Caramazza D, Pieri L, Rumi E, Gisslinger H, Knoops L, Kiladjian JJ, Mora B, Hollaender N, Pascutto C, Harrison C, Cazzola M. Passamonti F, et al. Among authors: kiladjian jj. Blood. 2014 Mar 20;123(12):1833-5. doi: 10.1182/blood-2013-12-544411. Epub 2014 Jan 17. Blood. 2014. PMID: 24443442 Free article. Clinical Trial.
Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Thiele J, et al. Michiels JJ, et al. Among authors: kiladjian jj. Neth J Med. 1999 Feb;54(2):46-62. doi: 10.1016/s0300-2977(98)00143-0. Neth J Med. 1999. PMID: 10079679 Review.
Long-term follow-up of recovered MPN patients with COVID-19.
Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Rossi G, Harrison C, Alvarez-Larran A, Elli EM, Kiladjian JJ, Gasior Kabat M, Marin Sanchez A, Palandri F, Andrade-Campos MM, Vannucchi AM, Carreno-Tarragona G, Papadopoulos P, Quiroz Cervantes K, Angeles Foncillas M, Fox ML, Sagues Serrano M, Rumi E, Osorio S, Benevolo G, Patriarca A, Navas Elorza B, Garcia-Gutierrez V, Magro Mazo E, Lunghi F, Bonifacio M, De Stefano V, Hernandez-Boluda JC, Lopez Abadia E, Angona A, Xicoy Cirici B, Ruggeri M, Koschmieder S, Sobas MA, Cuevas B, Cattaneo D, Daffini R, Bellini M, Curto-Garcia N, Garrote M, Cavalca F, Benajiba L, Bellosillo B, Guglielmelli P, Borsani O, Betti S, Salmoiraghi S, Rambaldi A. Barbui T, et al. Among authors: kiladjian jj. Blood Cancer J. 2021 Jun 16;11(6):115. doi: 10.1038/s41408-021-00509-0. Blood Cancer J. 2021. PMID: 34135309 Free PMC article. No abstract available.
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19.
Barbui T, De Stefano V, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Cancelli V, Elli EM, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Carli G, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, Harrison C, Rambaldi A, Vannucchi AM. Barbui T, et al. Among authors: kiladjian jj. Blood Cancer J. 2021 Feb 4;11(2):21. doi: 10.1038/s41408-021-00417-3. Blood Cancer J. 2021. PMID: 33563901 Free PMC article.
295 results